ライフサイエンスコーパス: FNA

1 FNA biopsies provide a diagnostic to rapidly phenotype t

2 FNA has had greatest efficacy in confirming celiac axis

3 FNA is a common method of diagnosis for pancreatic cance

4 FNA material was separately cultured for a short time in

5 FNA samples from melanoma xenografts showed comparable e

6 FNA samples from patients with metastatic melanoma succe

7 FNA samples were representative of the tumor as a whole

8 FNA samples yielded greater numbers of viable cells when

9 FNA sequencing is feasible and subsets of patients may h

10 FNA sequencing opens the door to clinical trials in whic

11 FNA treatment decreased the biomass-specific N2O product

12 FNA was performed in 133 (98.5%) patients with RLN, with

13 FNA was performed in 133 (98.5%) patients with RLNs, wit

14 FNA-derived cultures were evaluated for anchorage-indepe

15 FNAs mainly include DNAzymes, G-quadruplexes, and mismat

16 FNAs that are expanded from a wide range of clinical bre

17 Of 115 FNA procedures, 93 were completed for the initial evalua

18 of the 470 patients underwent a total of 115 FNA procedures, which were assessed by more than 70 diff

19 models of metastatic melanoma, as well as 12 FNA samples from patients with metastatic melanoma.

20 ese cutoffs in two independent datasets: 123 FNA samples and 177 tissue samples (ie, resected or core

21 49 true-negative (TN, 18%), and 34 FN (13%) FNA results.

22 nd 8 tumor cell lines were generated from 18 FNA (12 patients).

23 For the 22 FNAs done for recurrent disease, only nine (41%) were cl

24 Seven of the 24 FNAs with immunophenotyping (29%) were correlated with s

25 Only one (2%) of 43 FNA diagnoses, based on morphology alone, was correlated

26 We collected a minimum of 6 FNA samples from each of 250 patients during EUS.

27 e paired comparisons, only eight (12%) of 67 FNA diagnoses were correlated with the subsequent excisi

28 Of the 93 FNA attempts at initial diagnosis, only 27 (29%) were gi

29 Sixty-seven (72%) of the 93 FNAs performed for the evaluation of initial disease had

30 eatment strategy based on free nitrous acid (FNA or HNO2) to enhance methane production from WAS.

31 ing sludge treatment with free nitrous acid (FNA) and free ammonia (FA).

32 ugh free ammonia (FA) and free nitrous acid (FNA) inhibition on nitrite-oxidizing bacteria (NOB).

33 ) that was established by free nitrous acid (FNA)-based sludge treatment was not higher but much lowe

34 studies demonstrate that free nitrous acid (FNA, i.e., HNO(2)) is biocidal for a range of microorgan

35 herein, we present a framework nucleic acid (FNA) capture for sensitive, rapid, and multiplexed imagi

36 Functional nucleic acid (FNA) nanotechnology is an interdisciplinary field betwee

37 Functional nucleic acid (FNA) nanotechnology is an interdisciplinary field betwee

38 ion sensors using functional nucleic acids (FNAs) and nanomaterials.

39 Functional nucleic acids (FNAs) are a class of biomolecules that can exhibit eithe

40 Nevertheless, additional FNA for PCF analysis improved the diagnostic performance

41 omaterials as elements for creating advanced FNA nanomaterials.

42 omaterials as elements for creating advanced FNA-nanomaterials.

43 ues or the use of instrument-based analysis, FNA-based biosensors are capable of entering cells witho

44 d forty-one (341) patients underwent EUS and FNA of a pancreatic cystic lesion; 112 of these patients

45 ved from usable spectra, the combined MR and FNA technique, as modified and implemented in this study

46 ollicular cell-derived neoplasia tissues and FNA biopsies.

47 g peripheral blood, bulk resected tumor, and FNA were analyzed from 13 mesothelioma patients.

48 ns between FNAs and nanomaterials as well as FNA self-assembly technologies have established themselv

49 ns between FNAs and nanomaterials as well as FNA self-assembly technologies have established themselv

50 osis of malignancy in fine-needle aspirates (FNA) and biliary brushing specimens from patients with p

51 lls within samples of fine-needle aspirates (FNA) can be propagated in culture.

52 ymphocytes (TIL) from fine needle aspirates (FNA) of tumors potentially allows a dynamic evaluation o

53 time evaluation with fine-needle aspiration (FNA) and combinations of chemical-shift MRI, noncontrast

54 ens obtained through fine-needle aspiration (FNA) and excisional biopsy were tested for M. tuberculos

55 years who underwent fine-needle aspiration (FNA) biopsy between January 2004 and July 2017 was analy

56 ytologic features on fine needle aspiration (FNA) biopsy require thyroidectomy because of a 20% to 30

57 sis was performed on fine needle aspiration (FNA) biopsy samples from four murine xenograft models of

58 kup with imaging and fine-needle aspiration (FNA) biopsy to evaluate for cancer.

59 f thyroid nodules on fine needle aspiration (FNA) cytology samples has given clinicians a new level o

60 pic ultrasound (EUS)/fine needle aspiration (FNA) for detection of MRLNs in extrahepatic CCA, but the

61 -guided percutaneous fine-needle aspiration (FNA) has become the procedure of choice for biopsies of

62 Fine-needle aspiration (FNA) is increasing in popularity as a means of diagnosin

63 ographic (US)-guided fine-needle aspiration (FNA) of axillary lymph nodes for preoperative staging of

64 CT-guided fine-needle aspiration (FNA) of lung lesions is subject to sampling errors.

65 diagnostics included fine needle aspiration (FNA) of suspicious lesions and mini-laparoscopy to estab

66 Fine-needle aspiration (FNA) of thyroid nodules has become the primary diagnosti

67 Fine-needle aspiration (FNA) or stereotactic core biopsy was used to diagnose 19

68 plified RNAs from 63 fine needle aspiration (FNA) samples from 37 s.c. melanoma metastases from 25 pa

69 Data from 195 fine-needle aspiration (FNA) samples were used to define mRNA cutoff values that

70 ng of thyroid nodule fine-needle aspiration (FNA) specimens has been proposed as an adjunct to the cy

71 chieved at EUS using fine-needle aspiration (FNA) to obtain cytology from suspect Ns.

72 ould be studied with fine-needle aspiration (FNA).

73 d effectively by EUS-fine needle aspiration (FNA).

74 ltrasonography (EUS) fine-needle aspiration (FNA).

75 imaging and guided, fine-needle aspiration (FNA).

76 ivo while performing fine needle aspiration (FNA).

77 Pretreatment of WAS for 24 h at FNA concentrations up to 2.13 mg N/L substantially enhan

78 Anatomy- and metabolism-based FNA guidance using information provided by both (18)F-FD

79 receptor binding decreased 24 hr after beta-FNA injection and returned to control levels 11 d after

80 In pretrained animals, beta-FNA significantly impaired spatial memory retrieval and

81 re, pretreatment with the mu antagonist beta-FNA (1.00-2.00 microg) attenuated antinociception induce

82 Behaviorally, beta-FNA prevented morphine-induced loss of righting and Stra

83 er degree by NTI, and was unaffected by beta-FNA.

84 ceptor antagonist, beta-funaltrexamine (beta-FNA) also results in opioid analgesia.

85 eceptor antagonist beta-funaltrexamine (beta-FNA) into area CA3.

86 ceptor antagonist, beta-funaltrexamine (beta-FNA), prior to parturition interfered with the establish

87 ceptor antagonist, beta-funaltrexamine (beta-FNA), prior to systemic morphine injection.

88 ceptor antagonist, beta-funaltrexamine (beta-FNA), was unilaterally infused into the PAG adjacent to

89 either naltrexone, beta-funaltrexamine (beta-FNA, mu), nor-binaltorphamine (NBNI, kappa) or naltrindo

90 re pretreated with beta-funaltrexamine (beta-FNA; 15 mg/kg s.c), an irreversible mu-opioid receptor a

91 NTB, beta-FNA, and nor-BNI were unable to block the cardioprotecti

92 Injections of beta-FNA into the CA3 region, but not into the ventricles, ca

93 ectivity, whereas the agonist effect of beta-FNA is clearly kappa opioid receptor (KOR) mediated.

94 Infusion of beta-FNA near specific medial thalamic nuclei attenuated morp

95 In the CPu of beta-FNA treated rats, morphine-induced c-Fos and JunB were a

96 ith the prototypic fumaroylamino opioid beta-FNA (1a) shows that they have similar MOR irreversible a

97 Ultra-low-dose NTX, nor-BNI or beta-FNA selectively antagonizes high-efficacy excitatory (hy

98 focuses on the study of interactions between FNAs and nanomaterials and explores the particular advan

99 focuses on the study of interactions between FNAs and nanomaterials and explores the particular advan

100 and nanomaterials, the interactions between FNAs and nanomaterials as well as FNA self-assembly tech

101 and nanomaterials, the interactions between FNAs and nanomaterials as well as FNA self-assembly tech

102 of these in fine needle aspiration biopsies (FNA).

103 ave developed a fine needle aspirate biopsy (FNA) platform to perform immune profiling on thoracic ma

104 of reactor operation, NOB adaptation to both FNA and FA was observed, but the adaptation was successf

105 iopsy and 15 of 195 (7.7%) were diagnosed by FNA or stereotactic core biopsy.

106 Clinical FNA smears were prospectively collected and analyzed usi

107 ted with 69 prospectively collected clinical FNA smears.

108 DNA from both simulated FNAs and clinical FNAs was sequenced.

109 have reported numerous methods to construct FNA nanomaterials.

110 ed numerous preparation methods to construct FNA-nanomaterials.

111 ith score 1 or 2 registration quality for CT FNA and PET/CT/CT images, including 179 TP (67%), 5 fals

112 T images performed for the FNA procedure (CT FNA) with corresponding slices of the PET/CT study.

113 rasound and fine-needle aspiration cytology (FNA).

114 ethods based on the combination of different FNAs and nanomaterials are discussed.

115 EBUS-FNA was more sensitive than TBNA, detecting 29 (69%) vs

116 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimated sensitivity (93

117 In particular, we aimed to compare EBUS-FNA with TBNA.

118 TBNA, EBUS-FNA, and EUS-FNA performed sequentially as a single comb

119 These findings suggest that EBUS-FNA has higher sensitivity than TBNA and that EUS plus E

120 iscuss the most successful methods employing FNAs and nanomaterials as elements for creating advanced

121 uss the most successful methods of employing FNAs and nanomaterials as elements for creating advanced

122 EUS FNA is more accurate for nodal staging and impacts on th

123 EUS FNA resulting in a higher/worse stage than CT (41 patien

124 EUS FNA should be included in the preoperative staging algor

125 EUS FNA was more sensitive (83% vs. 29%; P < 0.001) than CT

126 formance characteristics of CT, EUS, and EUS FNA for preoperative nodal staging of esophageal carcino

127 d tumor stage determined by CT, EUS, and EUS FNA were associated with treatment decisions (P < 0.05).

128 rospectively evaluated with CT, EUS, and EUS FNA.

129 le of EUS-guided fine-needle aspiration (EUS FNA) in this setting is unclear.

130 EUS-FNA as a first test (after CT) has high diagnostic yield

131 EUS-FNA established tissue diagnosis in 70% of cases.

132 EUS-FNA has good accuracy in PCLs < 3 cm.

133 EUS-FNA identified MRLN in 27 of 31 (87.1%) patients ultimat

134 EUS-FNA identified MRLN in27/31 (87.1%) patients ultimately

135 EUS-FNA is able to detect occult metastasis to the CLNs and

136 EUS-FNA is effective for identifying MRLN in patients with C

137 EUS-FNA sampling was diagnostic in 72 of 92 cases (78.3%).

138 EUS-FNA was also useful to diagnose benign cysts, possibly a

139 EUS-FNA was performed in 457 patients with 554 lesions.

140 EUS-FNA was significantly better than CT at detecting distan

141 EUS-FNA with histology of the specimens is a sensitive and a

142 EUS-FNA, CT, and positron emission tomography detected metas

143 a more indolent clinical course; and (3) EUS-FNA may be useful for the diagnosis and management of GI

144 TBNA, EBUS-FNA, and EUS-FNA performed sequentially as a single combined procedur

145 trasound-guided, fine-needle aspiration (EUS-FNA) biopsy and were resected.

146 ltrasound-guided fine-needle aspiration (EUS-FNA) for diagnosis of metastases to the pancreas.

147 ltrasound-guided fine needle aspiration (EUS-FNA) for the diagnosis of solid pancreatic cancer is inc

148 ultrasound with fine-needle aspiration (EUS-FNA) is recommended in pancreatic cystic lesions (PCLs)

149 onography-guided fine needle aspiration (EUS-FNA) of pancreatic cysts, but there is conflicting evide

150 ultrasound with fine needle aspiration (EUS-FNA) remain the preferred methods.

151 ltrasound-guided fine needle aspiration (EUS-FNA) was allowed as an alternative procedure.

152 ltrasound-guided fine needle aspiration (EUS-FNA) was evaluated as a single test for the diagnosis an

153 ltrasound-guided fine-needle aspiration [EUS-FNA]) is capable of sampling lymph nodes for PCR analysi

154 firmed in 32 (1.6%) cases, 30 of them by EUS-FNA, and 2 by surgery.

155 -guided fine needle aspiration cytology (EUS-FNA), and the newest emerging application is EUS-guided

156 Minimally invasive EUS-FNA with RT-PCR is capable of detecting expression of ca

157 The diagnostic yields of EUS-FNA and CT for detection of metastases to the CLNs were

158 The combination of EUS-FNA and EBUS-FNA (EUS plus EBUS) had higher estimated se

159 Limited data supports the utility of EUS-FNA for detection of MRLN in extrahepatic CCA, but there

160 The performance of EUS-FNA for diagnosis of pancreatic metastases was analyzed.

161 The sensitivity of EUS-FNA for pancreatic adenocarcinoma is excellent (more tha

162 A multicenter prospective evaluation of EUS-FNA for primary diagnosis, staging, and/or follow-up pur

163 re prospectively the diagnostic yield of EUS-FNA samples obtained with slow-pull (SP) and with standa

164 ative predictive values, and accuracy of EUS-FNA with histology analysis of the specimens for diagnos

165 Performance of EUS-FNA with PCF analysis for the detection of malignancy an

166 diagnosis was based on a combination of EUS-FNA, surgery and follow-up of minimum 6 months in negati

167 for EUS, but most of the emphasis is on EUS-FNA and EUS-guided interventions.

168 nd fluorescence in-situ hybridization on EUS-FNA samples may increase the yield and prove to be bette

169 atients with a pancreatic cyst requiring EUS-FNA at multiple centers in Spain.

170 cases with resectable tumor on CT scan, EUS-FNA avoided thoracotomy in 14% of cases.

171 ile FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and complete

172 hat FDG-PET/CT may be more accurate than EUS-FNA and CT scan for predicting nodal status and complete

173 randomized trial of patients undergoing EUS-FNA for pancreatic cyst evaluation, we found the risk of

174 dy of PCLs < 3 cm (2007-2016) undergoing EUS-FNA.

175 37 patients underwent EUS-FNA for probable pancreas metastases.

176 revious extrapancreatic cancer underwent EUS-FNA from January/1997 to December/2010.

177 ients from the EBUS-TBNA group underwent EUS-FNA.

178 patients with PCLs < 3 cm who underwent EUS-FNA.

179 ediastinal lymph nodes were sampled with EUS-FNA in patients with NSCLC and negative control subjects

180 oregional staging is best performed with EUS-FNA, with CT scan of the thorax and abdomen and FDG-PET,

181 red for cases with true-positive (TP) and FN FNA results.

182 For FNA specimens, the sensitivity was 17.1%, and the specif

183 to the limited quantity of DNA derived from FNA specimens and tumor heterogeneity.

184 who underwent (18)F-FDG PET/CT and CT-guided FNA within an interval of less than 30 d were retrospect

185 e and thus improve the accuracy of CT-guided FNA.

186 Endoscopic ultrasonography-guided FNA biopsy may play a valuable role in the evaluation of

187 results on endoscopic ultrasonography-guided FNA biopsy were positive in 57 patients, negative in 37,

188 eatitis on endoscopic ultrasonography-guided FNA biopsy.

189 underwent endoscopic ultrasonography-guided FNA biopsy.

190 ristics of endoscopic ultrasonography-guided FNA for diagnosing pancreatic masses were determined.

191 stochemical analysis using ultrasound-guided FNA biopsy, guiding the clinician to nodal excision rath

192 US-guided FNA did not result in any intra- or postprocedural compl

193 ical intervention after diagnostic US-guided FNA findings, results of surgical-pathologic analysis he

194 Sensitivity of US-guided FNA for predicting positive results at ALND or SNB was 7

195 nodules (n = 5349) that underwent US-guided FNA in 2004-2012 were identified; 393 were single nodule

196 US-guided FNA in the most suspicious node at US, or the largest no

197 Sensitivity of US-guided FNA increased with primary tumor size.

198 The diagnostic accuracy of US-guided FNA is similar to that of core needle biopsy, and there

199 US-guided FNA of axillary lymph nodes in patients with newly diagn

200 ars]) who underwent 52 consecutive US-guided FNA procedures from 2004 to 2009 were reviewed.

201 US-guided FNA results in 74 patients with breast cancer (75 axilla

202 compared with US and preoperative US-guided FNA results.

203 ositive predictive value of US and US-guided FNA were calculated.

204 tion on the basis of findings from US-guided FNA.

205 We hypothesize that free nitrous acid (HNO2, FNA) may assist in the (partial) disruption of extracell

206 ave been used as in vivo biosensors, and how FNAs can be coupled to transduction systems and delivere

207 However, FNA cytology does not allow differentiation between foll

208 ve about the issues and developing trends in FNA nanotechnology.

209 In FNAs obtained from 17 patients with unresectable disease

210 In FNAs, genetic alterations were detected in 19/44 maligna

211 methane production increased with increased FNA concentration used in the pretreatment step.

212 e substrates, which increased with increased FNA dose, while the slowly biodegradable substrates rema

213 f surgery in a patient with an indeterminate FNA biopsy.

214 of malignancy in cytologically indeterminate FNAs.

215 a possible diagnostic tool for indeterminate FNAs, and as a determinant for planning initial clinical

216 Model-based analysis indicated FNA pretreatment improved both hydrolysis rate and metha

217 , while during a steady state, it was mainly FNA, which was responsible for inhibitory effects due to

218 l thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocytic/Hurthle cell, 2 medullary, 1 follicular

219 he feasibility of TIL expansion from minimal FNA material and localization of vaccine-specific T cell

220 y ranged from $746 (NP-59) to $1745 (MRI +/- FNA).

221 2839 (CT0) and 759 (NP-59) and 1982 (MRI +/- FNA) for cost and diagnostic accuracy, respectively.

222 a novel approach termed flexible nanoarray (FNA) in which the interaction between the two internally

223 A negative FNA does not reliably rule out infection.

224 Yet, up to 20% of thyroid nodule FNA biopsies will be indeterminate in diagnosis based on

225 osed with repeat FNA following nondiagnostic FNA results (two of 336, 0.6%); therefore, clinical and

226 ; 393 were single nodules with nondiagnostic FNA results but adequate cytologic, surgical, or US foll

227 Given that 60% of FNA biopsy specimens yielded no usable spectra and that

228 analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious resul

229 e used to improve the diagnostic accuracy of FNA biopsy.

230 urance criteria to determine the accuracy of FNA procedures to sample tumor tissue.

231 piration in lung lesions and the accuracy of FNA results.

232 biomaterials that combine the advantages of FNA and nanomaterials, the interactions between FNAs and

233 lly, we review the extensive applications of FNA nanomaterials in bioimaging, biosensing, biomedicine

234 he particular advantages and applications of FNA nanomaterials.

235 end, we review the extensive applications of FNA-nanomaterials in bioimaging, biosensing, biomedicine

236 he particular advantages and applications of FNA-nanomaterials.

237 The only case of FNA-related infection (0.44%) occurred in a patient in t

238 2) and *NO) formed from the decomposition of FNA.

239 rovides insight into the biocidal effects of FNA on microorganisms.

240 hors also discuss some of the limitations of FNA and how to optimize the procurement and utilization

241 The biocidal mechanisms of FNA are largely unknown.

242 f ACR TI-RADS would have changed the rate of FNA (eg, decreased the number of procedures) and whether

243 This review offers a summary of FNA- and nanomaterial-based metal ion detection methods.

244 Molecular testing of FNA specimens may help to avoid diagnostic thyroidectomy

245 modified and used to examine the utility of FNA biopsies in the evaluation of suspicious breast lesi

246 biomaterials that combine the advantages of FNAs and nanomaterials, the interactions between FNAs an

247 structural and functional group features of FNAs and nanomaterials develop rapidly, many laboratorie

248 structural and functional group features of FNAs and nanomaterials rapidly develops, many laboratori

249 The roles of FNAs and nanomaterials are introduced first.

250 eview is to examine how molecular testing of FNAs could be used to guide surgical decision-making.

251 Here, we review the types of FNAs that have been used as in vivo biosensors, and how

252 ative frequency of indeterminate cytology on FNA could necessitate surgery in a large number of patie

253 ed on every other specimen (from every other FNA pass); patients were randomly assigned to the first

254 Overall, FNA for lymphoma diagnosis is not helpful, not cost effe

255 otyping was completed on 24 of the 67 paired FNAs.

256 patients with enlarging or symptomatic post-FNA pneumothoraces treated with a small-caliber catheter

257 Moreover, preoperative FNA sequencing has the potential to influence the timing

258 ortion of thyroid carcinomas in preoperative FNAs in our cohort and thus is not sufficient to rule ou

259 ic TIL could be expanded from prevaccination FNA.

260 The programmable FNA is designed using three DNA triangular prism (DTP) n

261 ollow-up may be more appropriate than repeat FNA following nondiagnostic biopsy results.

262 .3%) were subsequently diagnosed with repeat FNA (n = 2, 0.5%) or surgical pathologic examination (n

263 few malignancies were diagnosed with repeat FNA following nondiagnostic FNA results (two of 336, 0.6

264 In a direct comparison of the same FNA also tested by an RNA-based gene expression classifi

265 Serial FNA of the same lesions were performed in five HLA-A*020

266 concordance was determined between simulated FNAs and that of the resected specimen.

267 DNA from both simulated FNAs and clinical FNAs was sequenced.

268 Comparison of simulated FNAs and matched tumor tissue exhibited a concordance fr

269 survival, thyroid cancer-specific survival, FNA, and histopathology were collected until January 201

270 It was found that FNA broke down a range of cell envelope molecules.

271 In this work, it is hypothesized that FNA will break bonds in molecules found in the cell enve

272 Microbial analysis revealed that FNA treatment decreased the microbial community diversit

273 n investigation of the mechanism showed that FNA treatment caused a shift of the stimulation threshol

274 The FNA design allowed reversible experiments in which the m

275 The FNA tether was synthesized with nonnucleotide phosphoram

276 used to register CT images performed for the FNA procedure (CT FNA) with corresponding slices of the

277 This excluded PBMC contamination of the FNA material.

278 bout the issues and developing trends of the FNA nanotechnology field.

279 these experiments, the thiolated end of the FNA tether was covalently immobilized on the AFM substra

280 The other end of the FNA tether was functionalized with biotin to form a nonc

281 ieved for both models when predicting on the FNA test set, which included 24 nodules with indetermina

282 The spectral data demonstrated that the FNA reactions proceeded via two general pathways.

283 This suggests that the FNA technique is capable of analyzing multiple intermole

284 by nontethered peptides, suggesting that the FNA tether has the necessary flexibility to enable assem

285 as been used along with the Bethesda Thyroid FNA Classification System to offer preoperative guidance

286 uary 1994 through December 2000, 709 thyroid FNAs were performed at a single institution.

287 TCGA-reported genomic alterations in thyroid FNAs.

288 in the reactor, have the ability to adapt to FNA and FA, respectively, but do not adapt to the altern

289 Review, we first introduce some widely used FNAs and nanomaterials along with their classification,

290 review, we first introduce some widely used FNAs and nanomaterials along with their classification,

291 average age, 54 years) were excised by using FNA and core biopsies and were collected between Septemb

292 The primary outcome was FNA-related infection.

293 Thyroid nodules whose FNA is diagnosed as highly suspicious for malignancy sho

294 th the total number of nodules biopsied with FNA in this clinic to determine if the use of ACR TI-RAD

295 umber of nodules that would be biopsied with FNA on the basis of ACR TI-RADS was compared with the to

296 h diverse pathologies who underwent EUS with FNA, despite limited tissue sampling for FISH analysis.

297 found in the cell envelope were treated with FNA at 6.09 mg N/L (NO(2)(-) = 250 mg N/L, pH 5.0) for 2

298 Information yielded with FNA cytology plays an integral role in clinical decision

299 sterol (NP-59) scintigraphy, with or without FNA, in a hypothetical cohort of 1000 patients with inci

300 13 mg HNO2-N/L) being six times that without FNA pretreatment (0.025 mg COD/mg VS, at 0 mg HNO2-N/L).